CHARACTERIZATION AND TARGETING OF THE MULTIPLE DNA SECONDARY STRUCTURES IN THE KRAS PROXIMAL PROMOTER TO MODULATE GENE EXPRESSION
KRAS is a well-validated drug target for anti-cancer therapy, yet no clinically useful drugs that directly inhibit its function currently exist. We aim to target KRAS at the transcriptional level, through DNA secondary structures.
Main Author: | Kaiser, Christine Elizabeth |
---|---|
Other Authors: | Hurley, Laurence H. |
Language: | en_US |
Published: |
The University of Arizona.
2015
|
Online Access: | http://hdl.handle.net/10150/559576 |
Similar Items
-
KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma
by: Sergiu Pasca, et al.
Published: (2019-10-01) -
Targeting the DNA replication stress phenotype of KRAS mutant cancer cells
by: Tara Al Zubaidi, et al.
Published: (2021-02-01) -
Kr-pok increases FASN expression by modulating the DNA binding of SREBP-1c and Sp1 at the proximal promoter
by: Bu-Nam Jeon, et al.
Published: (2012-04-01) -
A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
by: Nicolas Bery, et al.
Published: (2020-06-01) -
Targeting the untargetable KRAS in cancer therapy
by: Pingyu Liu, et al.
Published: (2019-09-01)